Most insurance plans either don’t cover Wegovy at all or attach strict conditions that disqualify the majority of people who want it. The reasons range from your employer choosing to exclude weight loss drugs from your plan, to not meeting specific medical criteria, to outright bans on covering obesity medications. Understanding exactly why your claim was denied is the first step toward figuring out whether you can do anything about it.
Your Employer May Have Excluded It
The most common reason for a Wegovy denial is simple: the drug isn’t on your plan at all. Each insurer and its chief medical officer decide whether to cover these medications, and employers who sponsor health plans can choose to exclude GLP-1 drugs entirely. This is more widespread than most people realize. Only 19% of large firms (200 or more workers) cover GLP-1 medications for weight loss. Among mid-size companies with 200 to 999 employees, that drops to 16%. Even among the largest employers with 5,000 or more workers, fewer than half (43%) include coverage.
The reason is cost. Wegovy has a list price around $1,300 per month, and as more employees started requesting it, many employers saw their pharmacy spending spike. In response, some have dropped coverage altogether, tightened eligibility requirements, or added lifestyle coaching programs as a condition of continued access, hoping employees will eventually stop the medication. If your plan categorizes Wegovy as an “excluded benefit,” no amount of medical documentation will change that through the normal prior authorization process. Your only options at that point are an appeal (more on that below), paying out of pocket, or waiting until your employer revisits the decision.
You May Not Meet the Medical Criteria
Even when a plan does cover Wegovy, the qualifying criteria can be surprisingly narrow. Most people assume a high BMI is enough. It often isn’t. Many insurers require you to have an obesity-related medical condition on top of your weight, such as high cholesterol, high blood pressure, type 2 diabetes, or sleep apnea. A BMI indicating obesity or overweight alone may not be sufficient.
The standard threshold most plans use is a BMI of 30 or above, or 27 or above with at least one weight-related health condition. But some plans go further. Maryland’s Medicaid program, for example, only covers Wegovy for patients with established cardiovascular disease (a prior heart attack, stroke, or documented peripheral artery disease) or a specific liver condition called metabolic dysfunction-associated steatohepatitis with moderate to advanced scarring. Those criteria are far stricter than what the FDA approved the drug for.
Plans also commonly require documentation of previous unsuccessful weight loss attempts. You may need to show that you’ve already tried diet and exercise changes, participated in a structured weight management program, or used other medications first. This “step therapy” approach forces you to fail cheaper options before the insurer will approve a more expensive one. If your doctor didn’t document those earlier efforts in your medical record, that gap alone can trigger a denial.
Prior Authorization Hurdles
Nearly all plans that cover Wegovy require prior authorization, meaning your doctor must submit paperwork proving you meet the plan’s criteria before the pharmacy will fill your prescription. This is where many denials happen, and they’re not always final.
Common reasons a prior authorization gets rejected:
- Missing documentation. Your records don’t include a recent BMI measurement (some plans require one within the last 90 days), or your doctor didn’t list your qualifying health conditions.
- Wrong billing codes. Incorrect diagnosis or procedure codes can cause an automatic denial even when you genuinely qualify.
- Prescriber requirements. Some plans require the prescription to come from or be reviewed by a specialist, such as a cardiologist for the cardiovascular indication or a gastroenterologist for liver-related use.
- Step therapy not completed. You haven’t documented trying lifestyle changes or lower-cost medications first.
A denial for one of these reasons doesn’t necessarily mean your plan won’t cover Wegovy. It may mean the paperwork needs to be resubmitted with the right information.
Medicare and Medicaid Limitations
If you’re on Medicare, coverage depends entirely on why your doctor is prescribing Wegovy. Federal law has historically prohibited Medicare from covering weight loss medications. However, in 2024 the FDA approved Wegovy for a second use: reducing the risk of heart attacks and strokes in adults with established cardiovascular disease who are also overweight or obese. That approval opened a narrow door. If your doctor prescribes Wegovy specifically to reduce cardiovascular risk and you have documented heart disease, your Part D plan can cover it, though you’ll still need to go through the plan’s standard prior authorization process.
For people on Medicare who don’t have established cardiovascular disease, a new short-term program called the Medicare GLP-1 Bridge is set to run from July 2026 through December 2027, providing access to certain GLP-1 drugs. Until then, if you’re on Medicare and don’t qualify under the cardiovascular indication, coverage remains unavailable. When Medicare does cover Wegovy, it will likely be placed on a specialty tier with coinsurance of 25% to 33%, meaning you’d still pay $325 to $429 per month based on the list price.
Medicaid coverage varies dramatically by state. Only 13 state Medicaid programs covered GLP-1 drugs for obesity treatment as of January 2026, and that number has actually been shrinking. California, New Hampshire, Pennsylvania, and South Carolina all recently eliminated obesity coverage to control costs. States are required to cover GLP-1s when prescribed for diabetes, cardiovascular disease, or sleep apnea, but covering them for obesity remains optional. Even in states that do cover it, prior authorization requirements can further limit access.
The Cardiovascular Approval Changed the Landscape
The FDA’s 2024 decision to approve Wegovy for cardiovascular risk reduction was a significant shift. Before that approval, insurers could broadly classify Wegovy as a “lifestyle” or “weight loss” drug, categories they’ve historically been reluctant to cover. The cardiovascular indication reframes it as a drug that prevents heart attacks and strokes, which falls squarely into the kind of medical necessity that insurance plans routinely cover.
If you have a history of heart attack, stroke, or peripheral artery disease and your BMI is 27 or higher, this indication may be your strongest path to coverage. Your doctor would prescribe Wegovy specifically for cardiovascular risk reduction rather than weight management. Some plans that exclude weight loss drugs will still cover the same medication under a cardiovascular diagnosis. It’s the same injection, but the billing code and stated purpose make the difference.
How to Appeal a Denial
Your denial letter should include the specific reason your claim was rejected. That reason determines your appeal strategy. If the denial says “not medically necessary,” you’ll want your doctor to write a letter detailing your weight-related health conditions, your BMI, and any previous weight loss attempts that failed. If it says “excluded procedure” or “excluded benefit,” you need to verify that the correct billing codes were used and make sure all of your conditions are documented. Heart disease, diabetes, sleep apnea, high blood pressure: anything relevant should appear in the appeal, because a single missing diagnosis can be the difference between approval and denial.
The Obesity Action Coalition recommends building your appeal around the exact language of the denial. Address each stated reason individually with supporting evidence. If your doctor prescribed Wegovy for weight loss but you also have cardiovascular disease, resubmitting under the cardiovascular indication with the correct codes may produce a different result. Appeals do succeed, particularly when the initial denial was caused by incomplete paperwork rather than a blanket plan exclusion.
Paying Without Full Coverage
If your insurance won’t cover Wegovy or your out-of-pocket cost is still high, Novo Nordisk (the manufacturer) offers a savings program. Patients with commercial insurance can pay as little as $25 per month, with the program covering up to $100 of the remaining cost each fill. For uninsured patients paying entirely out of pocket, prices through the program start at $149 per month for the 1.5 mg or 4 mg doses and $199 per month for the standard pen, though these promotional prices are scheduled to increase after mid-2026. After that, self-pay pricing rises to $349 per month for standard doses and $399 for the higher-dose pen. People enrolled in Medicare, Medicaid, or other government programs are not eligible for the savings card.